American Vanguard
American Vanguard's revenue fell 5.9% to $515 million in fiscal 2025. Its operating margin was −5.5%, up from −18.6% a year earlier. Free cash flow was −$25 million. The diluted share count rose 1.3%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What American Vanguard does
American Vanguard makes and sells chemicals and biological products that protect crops, lawns, ornamental plants and animals from insects, weeds, fungi and other pests. Its range includes insecticides, herbicides, fungicides, soil fumigants, plant nutrition and growth regulators, sold as liquids, powders and granules. It also sells some products in closed containers that farmers load straight into their equipment without handling the chemical.
The company reports one business segment. Its main U.S. subsidiary, AMVAC, sells mostly through national distributors and buying groups, which resell to retailers and growers. Abroad it has sales offices or its own distributors in Central and South America, Australia, New Zealand and India. Its three largest customers made up 13%, 12% and 12% of sales in 2025. It says it competes with U.S. and foreign makers, many of them larger, on quality, how well products work, price and service.
American Vanguard is based in Newport Beach, California, runs six manufacturing plants and had 739 employees at the end of 2025. Demand is seasonal and follows growing seasons, weather and pest pressure. In 2025 it worked on a plan to cut supply chain and factory costs and simplify how it is organized. Its products must be registered with the U.S. Environmental Protection Agency, each state and foreign regulators.
Its biggest risks, as it describes them
- Regulators could limit or cancel some of its pesticides, as with the EPA's findings on DCPA and petitions against its organophosphate products.
- Lawsuits claiming harm from its products, and state laws banning certain pesticides, could hurt its results.
- Its new debt terms limit its cash, require minimum financial performance and carry significant interest costs.
- Bad weather and low crop prices can cut demand from farmers for its products.
- Disruptions in its global supply chain, including sourcing outside the U.S., and tariffs could raise costs or cut supply.
Income statement
From fiscal 2016 to 2023, earnings per share fell 7.2% a year and net income 7.4% a year, while buybacks cut the share count by 3%. American Vanguard then lost money in fiscal 2024 and 2025.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 16 | 20 | 11 | 12 | 12 |
| Debt incl. finance leases | 52 | 52 | 139 | 147 | 174 |
| Net debt (negative means net cash) | 36 | 31 | 128 | 135 | 162 |
| Net debt to EBITDA | 0.9x | 0.6x | 4.3x | — | — |
| Debt to equity | 0.1x | 0.1x | 0.4x | 0.6x | 0.9x |
| Interest coverage | 8.4x | 10.3x | 1.8x | −6.1x | −1.5x |
| Current ratio | 1.5x | 1.5x | 1.9x | 1.6x | 1.8x |
| Quick ratio | 0.8x | 0.8x | 0.9x | 0.9x | 0.9x |
Cash flow
Projections
Project American Vanguard's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What American Vanguard says to expect
- Full year 2026: adjusted EBITDA and sales
Revise Full-Year Outlook; Adjusted EBITDA $36 million to $40 million on Sales of $500 million to $530 million
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 3 insiders bought $237,110 of American Vanguard shares on the open market, and 1 insider sold $1.2 million.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 18, 2026 | Cruiser Capital Advisors LLCOther | Sold | 556,580 | $2.20 | $1.2 million | Form 4 |
| Aug 17, 2026 | Steven D MacicekDirector | Bought | 19,000 | $2.09 | $39,710 | Form 4 |
| Jun 3, 2026 | Douglas KayeChief Executive Officer | Bought | 5,000 | $2.50 | $12,500 | Form 4 |
| May 19, 2026 | Patrick E GottschalkDirector | Bought | 25,000 | $2.70 | $67,500 | Form 4 |
| May 13, 2026 | Patrick E GottschalkDirector | Bought | 20,000 | $2.95 | $59,000 | Form 4 |
| May 12, 2026 | Patrick E GottschalkDirector | Bought | 20,000 | $2.92 | $58,400 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 3 of 9 | 3 of 9 | 5 of 9 |
| Rule of 40 | −17.1% | −6.2% | −10.8% |
| Altman Z'' | 4.32 | 2.09 | 2.80 |
| Accruals ratio | 8.9% | −18.6% | −4.7% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Pass | Fail | Fail |
| Cash from operations is positive | Fail | Pass | Fail |
| Return on assets rose | Fail | Fail | Pass |
| Cash from operations exceeds net income | Fail | Pass | Pass |
| Debt fell relative to assets | Fail | Fail | Fail |
| Current ratio rose | Pass | Fail | Pass |
| Share count didn't rise | Pass | Pass | Fail |
| Gross margin rose | Fail | Fail | Pass |
| Revenue rose relative to assets | Fail | Fail | Pass |
| F-score | 3 of 9 | 3 of 9 | 5 of 9 |
Compare
Put American Vanguard side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| American Vanguard | FY25 | −5.9% | −5.5% | −4.9% | −6.2% | — | 5 | |
| LSB Industries | FY25 | 17.8% | 9.3% | 2.9% | 5.3% | 2.2x | 8 | Compare |
| Intrepid Potash | FY25 | 17.1% | 3.6% | 8.6% | — | — | — | Compare |
| Compass Minerals | FY25 | 11.3% | 2.0% | 10.3% | 1.8% | 6.1x | 5 | Compare |
| Scotts Miracle-Gro | FY25 | −3.9% | 10.5% | 8.0% | 13.4% | 4.8x | 6 | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 312 | 355 | 454 | 468 | 459 | 558 | 610 | 579 | 547 | 515 |
| Revenue growth | 7.9% | 13.8% | 27.9% | 3.1% | −2.0% | 21.6% | 9.3% | −5.0% | −5.5% | −5.9% |
| Gross profit | 128 | 147 | 183 | 177 | 173 | 171 | 192 | 179 | 120 | 148 |
| Research and development | 21 | 26 | 26 | 24 | 26 | 29 | 32 | 38 | 33 | 23 |
| Operating income | 20 | 27 | 39 | 26 | 23 | 31 | 41 | 23 | −102 | −28 |
| Net income | 13 | 20 | 24 | 14 | 15 | 19 | 27 | 8 | −126 | −50 |
| Diluted EPS (US$) | 0.44 | 0.68 | 0.81 | 0.46 | 0.51 | 0.61 | 0.92 | 0.26 | −4.50 | −1.75 |
| Diluted shares (millions) | 29 | 30 | 30 | 30 | 30 | 30 | 30 | 28 | 28 | 28 |
| Cash flow | ||||||||||
| Cash from operations | 46 | 59 | 12 | 10 | 90 | 86 | 57 | −59 | 4 | −21 |
| Capital expenditure | 11 | 7 | 8 | 13 | 11 | 10 | 13 | 12 | 7 | 4 |
| Free cash flow | 36 | 52 | 4 | −3 | 79 | 77 | 44 | −71 | −3 | −25 |
| Dividends paid | 1 | 2 | 2 | 2 | 1 | 2 | 3 | 3 | 2 | 0 |
| Share buybacks | 0 | 0 | 7 | 3 | 0 | 5 | 34 | 16 | 0 | 0 |
| Acquisitions | 0 | 82 | 20 | 38 | 19 | 10 | 0 | 5 | 0 | 0 |
| Stock-based compensation | 3 | 5 | 6 | 7 | 7 | 7 | 6 | 6 | 4 | 2 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 8 | 11 | 6 | 7 | 16 | 16 | 20 | 11 | 12 | 12 |
| Debt incl. finance leases | 41 | 78 | 97 | 149 | 107 | 52 | 52 | 139 | 147 | 174 |
| Total assets | 430 | 536 | 594 | 670 | 680 | 694 | 726 | 768 | 637 | 596 |
| Total liabilities | 148 | 230 | 264 | 326 | 320 | 321 | 356 | 398 | 404 | 404 |
| Shareholders' equity | 282 | 305 | 329 | 344 | 361 | 373 | 370 | 370 | 233 | 192 |
| Margins and ratios | ||||||||||
| Gross margin | 41.1% | 41.5% | 40.2% | 37.9% | 37.6% | 30.6% | 31.6% | 30.9% | 22.0% | 28.6% |
| Operating margin | 6.6% | 7.5% | 8.6% | 5.6% | 5.0% | 5.5% | 6.7% | 4.0% | −18.6% | −5.5% |
| Net margin | 4.1% | 5.7% | 5.3% | 2.9% | 3.3% | 3.3% | 4.5% | 1.3% | −23.1% | −9.7% |
| Free cash flow margin | 11.5% | 14.7% | 0.8% | −0.7% | 17.2% | 13.8% | 7.2% | −12.2% | −0.6% | −4.9% |
| Rule of 40 (growth + FCF margin) | 19.3% | 28.5% | 28.7% | 2.3% | 15.2% | 35.4% | 16.5% | −17.1% | −6.2% | −10.8% |
| Return on capital | 4.5% | 6.4% | 7.2% | 4.2% | 4.1% | 5.0% | 7.7% | 3.8% | −18.5% | −6.2% |
| Return on equity | 4.7% | 6.9% | 7.6% | 4.0% | 4.3% | 5.1% | 7.4% | 2.0% | −41.9% | −23.4% |
| Return on assets | 3.0% | 4.2% | 4.3% | 2.1% | 2.3% | 2.7% | 3.9% | 1.0% | −18.0% | −8.1% |
| Net debt to EBITDA | 0.9x | 1.5x | 1.6x | 3.2x | 2.1x | 0.9x | 0.6x | 4.3x | — | — |